As of 2024-12-12, the Intrinsic Value of Krystal Biotech Inc (KRYS) is
0.25 USD. This KRYS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 187.12 USD, the upside of Krystal Biotech Inc is
-99.90%.
The range of the Intrinsic Value is (51.11) - 6.01 USD
KRYS Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(51.11) - 6.01 |
0.25 |
-99.9% |
| DCF (Growth 10y) |
4.53 - (59.22) |
(1.96) |
-101.0% |
| DCF (EBITDA 5y) |
13.58 - 14.47 |
13.81 |
-92.6% |
| DCF (EBITDA 10y) |
10.33 - 10.13 |
10.14 |
-94.6% |
| Fair Value |
9.11 - 9.11 |
9.11 |
-95.13% |
| P/E |
9.25 - 100.34 |
49.27 |
-73.7% |
| EV/EBITDA |
27.81 - 69.93 |
45.42 |
-75.7% |
| EPV |
(12.33) - (31.48) |
(21.90) |
-111.7% |
| DDM - Stable |
9.28 - 56.11 |
32.69 |
-82.5% |
| DDM - Multi |
2.00 - 10.38 |
3.45 |
-98.2% |
KRYS Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
5,381.57 |
| Beta |
1.97 |
| Outstanding shares (mil) |
28.76 |
| Enterprise Value (mil) |
5,007.60 |
| Market risk premium |
4.60% |
| Cost of Equity |
12.33% |
| Cost of Debt |
5.00% |
| WACC |
8.00% |